1. Publication
- Title: Remote Multicomponent Rehabilitation in Intensive Care Unit Survivors: A Randomized Clinical Trial
- Acronym: iRehab
- Year & Journal: JAMA, published May 18, 2026
- Citation: O'Neill B, Bradley JM, Connolly B, et al; iRehab Trial Investigators. Remote Multicomponent Rehabilitation in Intensive Care Unit Survivors: A Randomized Clinical Trial. JAMA. 2026. doi:10.1001/jama.2026.7401
2. Context & Rationale
Background: Post-ICU survivorship is common, disabling, and resource-intensive — survivors frequently experience persistent physical deconditioning, fatigue, impaired daily activities, dysphagia/respiratory symptoms, anxiety, depression, cognitive problems, and reduced health-related quality of life (HRQoL). Evidence for post-hospital-discharge rehabilitation has been inconsistent, partly due to variation across trials in population, timing, and intensity.
Research Question/Hypothesis: In adult survivors of critical illness discharged home after an ICU admission requiring ≥48 hours of invasive mechanical ventilation, does a 6-week remote multicomponent rehabilitation program improve HRQoL, physical function, fatigue, mood, and other health-related outcomes at 8 weeks, compared with standard care?
Why This Matters: Post-ICU rehabilitation is underfunded and access is limited; a scalable, fully remote delivery model (if effective) could substantially expand access to survivorship care.
3. Design & Methods
- Study Type: Pragmatic, randomized controlled, open-label, assessor-blind, multicenter, clinical and cost-effectiveness trial with internal pilot
- Setting & Centers: 52 NHS hospitals, UK; managed by Warwick Clinical Trials Unit, led by Ulster University and Queen's University Belfast
- Population:
- Inclusion: Adults within 12 weeks of hospital discharge following ICU admission requiring ≥48h invasive mechanical ventilation (mean ventilation duration 11.32 days)
- Screening funnel: 3705 screened, 429 randomized (a third of excluded patients, ~1100, declined to participate) — reflecting a highly selected, motivated, relatively robust survivor population (median age 55; <1% six-month mortality)
- Intervention: 6-week remote multicomponent rehabilitation: weekly symptom management, exercise, and other components delivered by a trained intervention team
- Comparator: Standard care
- Blinding: Open-label treatment delivery; assessor-blind outcome assessment
- Statistical Power & Follow-Up: 428 planned (197 control, 231 intervention); primary outcome assessed at 8 weeks (HRQoL, physical function, fatigue, mood, and other health-related outcomes).
4. Key Results
429 randomized across 52 NHS hospitals.
Outcome | Intervention | Control | Notes |
HRQoL at 8 weeks (primary) | Not reported as exact score in accessible text | Not reported as exact score in accessible text | Overall primary result described as failing to improve HRQoL at 8 weeks per independent reporting |
Subgroup: shorter ventilation duration | Meaningful improvement | — | Patients with shorter mechanical ventilation duration showed meaningful recovery benefit from the program |
Mortality at 6 months | 3 deaths total (<1%) across the highly selected cohort | — | Reflects the relatively robust, younger, motivated population enrolled |
Note on data completeness: Exact numeric HRQoL scores, between-group differences, and confidence intervals were not available in the accessible source text; the overall primary-outcome conclusion ("failed to improve HRQoL... at 8 weeks") and the shorter-ventilation-duration subgroup signal are drawn from independent secondary reporting (Healio, PulmCCM) of the JAMA publication rather than the primary article's exact statistics.
5. Internal Validity Assessment
- Randomization & Allocation: Randomized, multicenter design; specific concealment mechanics not detailed in available trial text.
- Protocol Adherence & Separation: The trial's institutional press release specifically highlights that "fully remote processes... are feasible from the consent stage through to intervention delivery" — suggesting good operational/logistic execution of the remote delivery model itself.
- Blinding & Detection Bias: Assessor-blind outcome assessment is a meaningful strength for a rehabilitation trial where treatment delivery cannot be blinded.
- Missing Data & Sensitivity Analyses: Not detailed in available trial text.
- Overall Internal Validity Conclusion: Moderate — assessor-blind design is a genuine strength; however, the overall null primary result combined with a substantial selection funnel (3705 screened → 429 randomized, with ~1100 eligible patients declining) raises the question of whether the enrolled population was too robust/motivated to show a measurable effect, versus the intervention genuinely lacking efficacy for the broader post-ICU population.
6. External Validity Assessment
- Population Representativeness: Highly selected: patients had to survive prolonged critical illness (mean ventilation 11.32 days) and then actively choose to participate (two-thirds of eligible patients did so) — mean age 55, minimal 6-month mortality (<1%), relatively preserved baseline function (able to perform sit-to-stand tests). This is not representative of the full, more frail/elderly modern ICU population.
- Practice Context: Fully remote delivery model, feasible within NHS infrastructure; may generalize well to other health systems with similar digital-health delivery capability.
- Overall External Validity Conclusion: Limited-to-moderate — the trial's own commentary (PulmCCM) explicitly notes that whether frail or elderly ICU survivors (more representative of today's general ICU population) would also benefit "would require another trial more representative of the standard population."
7. Strengths & Limitations
Strengths:
- Demonstrates feasibility of fully remote trial conduct and intervention delivery, from consent through completion
- Assessor-blind outcome assessment
- Large, multicenter (52-hospital) UK NHS trial addressing a genuine, underfunded survivorship care gap
- Embedded cost-effectiveness analysis
Limitations:
- Overall primary outcome (HRQoL at 8 weeks) was negative
- Highly selected population (robust, younger, motivated survivors) limits generalizability to the broader, more frail modern ICU survivor population
- Exact primary-outcome statistics not accessible for this summary
- Substantial pre-randomization attrition (aptitude/willingness to participate) likely selected for patients less likely to show a measurable rehabilitation benefit ceiling effect
8. Interpretation & Practice Impact
- Clinical Implications: Remote multicomponent rehabilitation did not improve overall HRQoL at 8 weeks in this relatively robust, motivated post-ICU survivor population, but a subgroup with shorter ventilation duration showed meaningful benefit — suggesting the intervention may have more value for less severely affected survivors rather than as a universal post-ICU rehabilitation strategy.
- Mechanistic Coherence: The population's near-zero 6-month mortality and relatively preserved baseline function suggest a possible ceiling effect limiting the intervention's ability to demonstrate benefit in this specific cohort.
- Systems-Level Takeaway: Demonstrates that fully remote post-ICU rehabilitation delivery is operationally feasible at scale (a meaningful finding for digital health infrastructure), even though the overall clinical effectiveness signal was not confirmed in the primary analysis.
9. Controversies & Subsequent Evidence
- Editorial Commentary: An accompanying JAMA editorial ("The future of survivorship in critical illness," Moncion, Smith-Turchyn, Kho) addresses the broader context of post-ICU rehabilitation trial design and interpretation.
- Guideline Integration: Chief investigator Brenda O'Neill has publicly emphasized that rehabilitation for critical illness survivors remains underfunded, and that iRehab's demonstration of remote-delivery feasibility is itself a significant contribution independent of the primary HRQoL result; the trial's real-world testimonials suggest meaningful patient-level benefit even where the powered primary statistical outcome was not met.
10. Summary & Executive Takeaway
Summary: iRehab randomized 429 relatively robust, motivated post-ICU survivors (screened from 3705, mean age 55, <1% six-month mortality) across 52 UK NHS hospitals to a 6-week remote multicomponent rehabilitation program or standard care. The overall primary outcome (HRQoL at 8 weeks) did not show significant improvement, though patients with shorter ventilation duration showed a meaningful benefit signal.
Overall Takeaway: iRehab demonstrates that fully remote post-ICU rehabilitation delivery is operationally feasible at scale, but did not confirm an overall HRQoL benefit in this highly selected, relatively robust survivor population — whether the intervention would benefit the more frail, elderly, and severely affected patients who make up much of today's general ICU population remains an open question requiring a more representative trial.
11. Bibliography
- Connolly BA, Barclay M, Davies C, et al. PRACTICE: development of a core outcome set for trials of physical rehabilitation in critical illness. Ann Am Thorac Soc. 2024;21(12):1742-1750.
- Moncion K, Smith-Turchyn J, Kho ME. The future of survivorship in critical illness [editorial]. JAMA. 2026.